Sapient Capital LLC Decreases Stock Position in Boston Scientific Corporation $BSX

Sapient Capital LLC lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 92.7% in the 1st quarter, Holdings Channel reports. The firm owned 9,141 shares of the medical equipment provider’s stock after selling 115,431 shares during the period. Sapient Capital LLC’s holdings in Boston Scientific were worth $574,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. bought a new position in Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the 4th quarter valued at approximately $26,000. Sfam LLC bought a new stake in Boston Scientific in the 4th quarter worth approximately $29,000. Finally, Eagle Bay Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.5%

Shares of NYSE:BSX opened at $49.14 on Wednesday. The firm has a market capitalization of $73.04 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 1.06 and a beta of 0.56. The business has a 50 day simple moving average of $45.78 and a two-hundred day simple moving average of $61.39. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the business posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. TD Cowen dropped their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Citigroup dropped their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Royal Bank Of Canada reduced their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, Barclays lowered their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 14,800 shares of company stock valued at $781,412 in the last quarter. 0.34% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.